Regeneron Pharmaceuticals (REGN) Accumulated Depreciation & Amortization (2009 - 2025)

Regeneron Pharmaceuticals has reported Accumulated Depreciation & Amortization for 17 years, with the latest figure at $543.7 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 53.54% year-over-year to $543.7 million; the trailing twelve-month figure through Dec 2025 stood at $543.7 million (up 53.54% YoY), and the FY2025 full-year result was $543.7 million, up 53.54% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $543.7 million, up from $354.1 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $543.7 million in Q4 2025, with the low at $281.1 million in Q4 2021.
• Average Accumulated Depreciation & Amortization over 5 years is $362.3 million, with a median of $328.8 million recorded in 2023.
• Year-over-year, Accumulated Depreciation & Amortization rose 7.69% in 2024 and jumped 53.54% in 2025.
• Tracing REGN's Accumulated Depreciation & Amortization over 5 years: stood at $281.1 million in 2021, then gained by 8.11% to $303.9 million in 2022, then grew by 8.19% to $328.8 million in 2023, then rose by 7.69% to $354.1 million in 2024, then soared by 53.54% to $543.7 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $543.7 million (Q4 2025), $354.1 million (Q4 2024), and $328.8 million (Q4 2023), per Business Quant data.

Peer Comparison